Search results
Heart disease: Moderate intake of choline may help reduce risk
Medical News Today· 1 day agoCholine is a nutrient essential for heart health and brain function and is found in many foods like...
Ventyx Biosciences stock holds at Neutral amid competitor's trial results By Investing.com
Investing.com· 1 hour agoThis drug is seen as a direct rival to Ventyx's own NLRP3 inhibitor, VTX3232. NodThera's NT-0796...
Statins for heart disease prevention could be recommended for far fewer Americans if new risk...
Science Daily· 3 days agoAt a population level, the number of adults recommended for statins could decrease from 45.4 million to 28.3 million. At the same time, the study showed that most people who would be recommended ...
New Analysis Finds Millions of People on Statins May Not Need Them
Healthline via AOL· 1 day agocardiovascular disease.” This includes equations like PCE and PREVENT. New analysis may be more...
Carl Weathers Honored by Directors Guild Foundation in Renaming of Golf Tournament
The Wrap via Yahoo News· 19 hours ago"We celebrate the invaluable contributions of this remarkable man that has enriched our community,"...
Man died at Tacoma immigration detention center of natural causes, medical examiner says
Tacoma News Tribune via Yahoo News· 2 days agoCharles Leo Daniel, a citizen of Trinidad and Tobago, died March 7 of hypertensive and ...
Jun 07 2024 This Week in Cardiology
Medscape· 6 days agoFirst, I want to offer huge thank you to Professor Andrew Clark and the British Cardiovascular Society (BCS) for inviting me to give the Paul Wood...
Statins may help prevent some forms of cancer, study finds
Medical News Today· 5 days agoStatin medications help keep cholesterol levels within a healthy range, but researchers are...
Esperion Therapeutics Target of Unusually High Options Trading (NASDAQ:ESPR)
ETF DAILY NEWS· 2 days agoEsperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) saw some unusual options trading activity on Monday. Investors bought 5,316 call options on the stock. This represents an increase ...
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $9.33 Consensus Target Price from Analysts
ETF DAILY NEWS· 1 day agoEsperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has earned an average rating of “Hold” from the five analysts that are currently covering the company, MarketBeat reports. Three research ...